Status:

COMPLETED

Recovery Protein Nutrition As a Countermeasure for Anabolic Resistance Following Sleep Loss

Lead Sponsor:

United States Army Research Institute of Environmental Medicine

Conditions:

Sleep, Inadequate

Eligibility:

All Genders

18-39 years

Phase:

NA

Brief Summary

The current study will determine protein nutritional status (MPS and WBPB) in response to military-relevant sleep loss, and whether an even protein nutrition distribution during recovery optimally sup...

Detailed Description

The nutritional fitness of Service Members directly influences recovery from operational stress. Inadequate recovery nutrition following military missions, including sleep loss, exacerbates skeletal m...

Eligibility Criteria

Inclusion

  • Adults aged 18 - 39 years
  • Body mass index \< 30.0 kg/m2
  • Self-report weight stable for the past 2 months (± \~3 kg)
  • Healthy without evidence of chronic illness, musculoskeletal injury, or diagnosed sleep disorder (i.e., insomnia) as determined by the USARIEM Office of Medical Support and Oversight (OMSO) or home duty station medical support
  • Self-report participates in aerobic and/or resistance exercise, on average, ≥2 days per week for previous 6 months
  • Willing to refrain from alcohol, smoking/using any nicotine product (includes e-cigarettes, vaping, chewing tobacco), caffeine, and dietary supplements during the intervention periods of the study
  • Supervisor approval for federal civilian employees and non-HRV active duty military personnel
  • Biological females must have normal menstrual cycles between 26-32 days in duration; 5 menstrual cycles within the past 6 months; or able to provide self-report documentation of sustained (i.e., \~ \>3 months) oral/hormonal contraceptive use which contains low-dose estrogen/progesterone to maintain continuous hormonal levels (i.e., IUD or no oral placebos)

Exclusion

  • Metabolic or cardiovascular abnormalities, gastrointestinal disorders (e.g., abnormal blood clotting, kidney disease, diabetes, cardiovascular disease, anemia etc.) as determined by OMSO or home duty station medical support
  • History of complications with lidocaine (or similar local anesthetic)
  • Present condition of substance abuse (e.g., alcoholism, anabolic steroid use etc.) as self-report or determined by OMSO or home duty station medical support
  • Cumulative blood donation of greater than 550mL within 8-wk of beginning scheduled study blood collection
  • Cumulative blood donation of greater than 550mL within 8-wk after completing scheduled study blood collection
  • Pregnant, trying to become pregnant, and/or breastfeeding (results of urine pregnancy test prior to body composition scans and self-report for breastfeeding)
  • Unwilling or unable to consume study diets or foods provided due to personal preference, dietary restrictions, and/or food allergies
  • Unwilling or unable to adhere to study physical restrictions or sleep prescriptions

Key Trial Info

Start Date :

March 21 2024

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 4 2024

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT06073080

Start Date

March 21 2024

End Date

November 4 2024

Last Update

January 27 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

US Army Research Institute of Environmental Medicine

Natick, Massachusetts, United States, 01760